This company has been marked as potentially delisted and may not be actively trading. NASDAQ:BFRA Biofrontera (BFRA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Biofrontera Stock (NASDAQ:BFRA) 30 days 90 days 365 days Advanced Chart Remove Ads Get Biofrontera alerts:Sign Up Key Stats Today's Range$2.51▼$2.7850-Day Range$2.50▼$3.6052-Week Range$2.09▼$7.54Volume7,263 shsAverage Volume27,512 shsMarket Capitalization$73.73 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBiofrontera AG engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.Read More… Remove Ads Receive BFRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biofrontera and its competitors with MarketBeat's FREE daily newsletter. Email Address BFRA Stock News HeadlinesBenchmark behält Kaufempfehlung für Biofrontera-Aktie bei, Kursziel 7 US-DollarMarch 24, 2025 | de.investing.comBiofrontera Inc. reports Q4 EPS (19c) vs $1.65 last yearMarch 22, 2025 | markets.businessinsider.comTrump to unlock 15-figure fortune for America (May 3rd) ?We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public. April 4, 2025 | Paradigm Press (Ad)Q4 2024 Biofrontera Inc Earnings CallMarch 22, 2025 | finance.yahoo.comEarnings Call Transkript: Biofrontera verzeichnet Umsatzwachstum und strategische Veränderungen in Q4 2024March 21, 2025 | de.investing.comBiofrontera completes patient enrollment in Phase 3 study of AmeluzMarch 19, 2025 | markets.businessinsider.comBiofrontera enrols all subjects in trial of topical gel for actinic keratosesMarch 19, 2025 | msn.comBiofrontera says last patient completed one-year follow-up in Ameluz-PDT studyJanuary 9, 2025 | markets.businessinsider.comSee More Headlines BFRA Stock Analysis - Frequently Asked Questions How were Biofrontera's earnings last quarter? Biofrontera AG (NASDAQ:BFRA) announced its earnings results on Wednesday, November, 24th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.03. The company had revenue of $6.34 million for the quarter. Biofrontera had a negative net margin of 59.44% and a negative trailing twelve-month return on equity of 93.31%. When did Biofrontera IPO? Biofrontera (BFRA) raised $18 million in an IPO on Wednesday, February 14th 2018. The company issued 1,500,000 shares at a price of $11.00-$13.00 per share. Benchmark acted as the underwriter for the IPO and Dawson James Securities and Lake Street Capital Markets were co-managers. What other stocks do shareholders of Biofrontera own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biofrontera investors own include AMC Entertainment (AMC), AC Immune (ACIU), Adaptimmune Therapeutics (ADAP), ADMA Biologics (ADMA), Ashford Hospitality Trust (AHT), Akebia Therapeutics (AKBA) and Assembly Biosciences (ASMB). Company Calendar Last Earnings11/24/2021Today4/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:BFRA CIK1712641 Webwww.biofrontera.com Phone(921) 487-6320Fax49-02-1487-6320Employees138Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,880,000.00 Net Margins-59.44% Pretax MarginN/A Return on Equity-93.31% Return on Assets-24.02% Debt Debt-to-Equity Ratio0.13 Current Ratio1.26 Quick Ratio1.13 Sales & Book Value Annual Sales$36.19 million Price / Sales2.04 Cash FlowN/A Price / Cash FlowN/A Book Value$0.35 per share Price / Book7.43Miscellaneous Outstanding Shares28,359,000Free FloatN/AMarket Cap$73.73 million OptionableNot Optionable Beta1.02 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:BFRA) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biofrontera AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Biofrontera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.